Last reviewed · How we verify
ASP8232
ASP8232 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.
ASP8232 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes. Used for Treatment of autoimmune diseases.
At a glance
| Generic name | ASP8232 |
|---|---|
| Sponsor | Astellas Pharma Europe B.V. |
| Drug class | PI3K delta and gamma inhibitor |
| Target | PI3K delta and gamma |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 2 |
Mechanism of action
By inhibiting these enzymes, ASP8232 is thought to modulate immune cell function and potentially treat various inflammatory and autoimmune diseases.
Approved indications
- Treatment of autoimmune diseases
Common side effects
- Diarrhea
- Nausea
- Vomiting
- Abdominal pain
- Fatigue
Key clinical trials
- A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney Disease (PHASE2)
- A Study to Evaluate ASP8232 in Reducing Central Retinal Thickness in Subjects With Diabetic Macular Edema (DME) (PHASE2)
- A Study to Evaluate the Pharmacokinetics, Pharmacodynamics and Safety of ASP8232 in Subjects With Renal Impairment and in Type 2 Diabetes Mellitus Subjects With Chronic Kidney Disease (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |